MercorPosted 5 Aug 2026

Biotech Investment Analyst — Drug Asset & Company Assessment

Pay

$120–200/hr

Work

Remote · Part time · 15 hrs/wk · Remote — US-based or deep US-market experience

Experience

5+ years

Eligibility

No stated location restriction

Field

Finance & accounting

Skills

Biotech Investment AnalysisPharmaceuticalsDrug Development ProgramsClinical Data AnalysisMechanism of ActionCompetitive AnalysisDrug Asset AssessmentCompany AssessmentInvestment Thesis EvaluationRubric Design and Critique

About this role

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.

Responsibilities

  • Create and critique rubrics that analyze commercial drugs and drug-development programs
  • Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
  • Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
  • Apply your assessment across the pilot's set of companies (~5–10)

Requirements

  • US-based biotech / healthcare investment analyst with a specialist-fund background
  • Familiarity with biotech/pharma development programs
  • Able to assess a drug asset and the company behind it end-to-end
  • 5+ years evaluating biotech/pharma companies or assets

Engagement Details

  • Duration: Approximately 10–20 hours over a 1–2 week pilot
  • Remote — US-based

Why Participate

  • Help improve expert AI evaluation of drugs and drug-development programs
  • Recurring engagement for strong contributors

Similar AI training jobs

All AI training jobs